Hub : Traits :

Crohns Disease (2012)

766 significantly associated models · 143 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	66697368	68152438	2	2	4.3e-30	1.1e-54	2.6e-43	22	IL23R MIER1
2	1	154325302	156671469	12	2	1.3e-10	3.6e-08	2.6e-01	96	ADAM15 MSTO2P
3	2	27971195	29344127	1	1	3.3e-08	4.6e-06	6.8e-02	84	RP11-373D23.3
4	2	61007782	61523554	1	1	4.9e-08	9.8e-08	3.1e-01	96	PEX13
5	2	101981794	103767612	4	1	4.5e-10	1.5e-10	1.0e+00	100	IL1RL1
6	2	233227833	234904144	3	1	1.8e-37	3.9e-38	1.0e+00	100	ATG16L1
7	3	47911521	50800146	19	1	8.4e-15	1.1e-13	1.1e-01	95	AMT
8	5	39986432	41555158	2	2	2.3e-12	4.5e-34	2.9e-22	36	CARD6 PTGER4
9	5	95519506	97065386	3	1	1.1e-11	9.4e-12	1.0e+00	100	LNPEP
10	5	129797129	132900729	16	8	1.8e-19	1.4e-20	NaN	NaN	C5orf56 P4HA2 PDLIM4 RAD50 SLC22A5
11	5	140789933	142230251	1	1	2.9e-08	6.1e-08	1.2e-01	92	NDFIP1
12	5	149124105	151236214	7	2	2.0e-18	1.6e-17	1.9e-01	98	ANXA6 DCTN4
13	5	158501850	159005439	1	1	2.4e-14	9.1e-17	7.7e-04	84	IL12B
14	6	166651581	167841508	3	1	6.0e-13	7.6e-12	1.9e-01	96	AL133458.1
15	9	4415824	5811733	1	1	2.2e-08	4.5e-11	1.1e-04	66	IGHEP2
16	9	116849447	118266112	1	1	7.6e-15	2.5e-15	7.2e-03	88	TNFSF15
17	9	138558883	140031290	7	1	5.0e-19	4.4e-20	1.0e+00	100	CARD9
18	10	34607015	36198981	2	1	1.8e-09	1.1e-09	1.0e+00	100	CUL2
19	10	59780998	60293294	1	1	2.5e-07	3.4e-07	1.0e+00	100	CISD1
20	10	63870456	65264300	2	1	7.1e-13	3.4e-19	7.2e-11	47	ADO
21	12	39904158	41454590	1	1	2.7e-10	7.9e-18	5.0e-09	54	LRRK2
22	13	43756650	45157394	1	1	3.4e-08	7.3e-09	1.0e+00	100	LACC1
23	15	66662107	68183665	1	1	2.9e-10	1.1e-12	9.1e-04	78	SMAD3
24	16	27655848	29595483	20	1	2.2e-12	9.3e-10	1.4e-01	94	EIF3C
25	16	49488151	51535063	5	8	3.2e-46	3.2e-61	1.3e-86	-43	ADCY7 CYLD NKD1 NOD2
26	17	32561182	33976619	1	1	2.6e-07	9.5e-12	6.6e-11	8	CCT6B
27	17	37137299	39048774	6	1	7.4e-09	2.4e-09	4.5e-02	89	PNMT
28	17	39863901	41265776	1	1	2.6e-07	2.9e-08	2.3e-02	83	PTRF
29	18	12538482	13133577	1	1	2.4e-14	5.1e-13	3.5e-01	98	PTPN2
30	19	9829303	11275258	2	2	2.5e-09	1.7e-08	4.1e-05	47	PDE4A S1PR5
31	19	48957497	49452462	1	1	4.1e-09	4.3e-09	1.0e+00	100	FUT2
32	20	61522825	62912463	8	1	2.5e-11	7.3e-11	1.0e+00	100	ARFRP1
33	21	45398656	45902320	1	1	2.0e-09	1.4e-13	7.6e-06	63	ICOSLG
34	22	21075537	22685340	4	1	1.2e-09	1.2e-09	1.0e+00	100	CCDC116

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Crohns Disease (2017)	40.59	44	43	95.6	0.99	2.8e-50	ADAM15 ADCY7 ADO AL133458.1 AMT ANXA6 ARFRP1 ATG16L1 C5orf56 CARD6 CARD9 CCDC116 CISD1 CUL2 CYLD DCTN4 EIF3C FUT2 ICOSLG IGHEP2 IL12B IL1RL1 IL23R LACC1 LNPEP LRRK2 MIER1 NDFIP1 NKD1 NOD2 P4HA2 PDE4A PDLIM4 PEX13 PNMT PTGER4 PTPN2 PTRF RAD50 RP11-373D23.3 S1PR5 SLC22A5 SMAD3 TNFSF15
Irritable Bowel Disease (IBD)	27.98	44	40	88.9	0.98	5.8e-34	ADAM15 ADCY7 ADO AL133458.1 AMT ANXA6 ARFRP1 ATG16L1 C5orf56 CARD6 CARD9 CCDC116 CISD1 CUL2 CYLD DCTN4 EIF3C FUT2 ICOSLG IGHEP2 IL12B IL1RL1 IL23R LACC1 LNPEP LRRK2 MIER1 NDFIP1 NKD1 NOD2 P4HA2 PDE4A PDLIM4 PEX13 PNMT PTGER4 PTPN2 PTRF RAD50 RP11-373D23.3 S1PR5 SLC22A5 SMAD3 TNFSF15
Blood Eosinophil Count	15.17	15	14	31.1	-0.41	9.1e-02	ADO C5orf56 CARD9 CCDC116 CUL2 IGHEP2 LNPEP NDFIP1 P4HA2 PDLIM4 PTPN2 RAD50 SLC22A5 SMAD3 TNFSF15
Ulcerative Colitis (UC)	9.57	18	12	26.7	0.94	2.7e-09	ADO AMT ARFRP1 CARD9 DCTN4 EIF3C ICOSLG IGHEP2 IL12B IL23R PDE4A PEX13 PNMT PTPN2 PTRF SLC22A5 SMAD3 TNFSF15
Asthma (self-reported)	9.45	11	8	17.8	-0.36	2.0e-01	ARFRP1 C5orf56 CUL2 LACC1 NDFIP1 P4HA2 PDLIM4 PNMT RAD50 SLC22A5 SMAD3
Asthma	9.37	11	7	15.6	-0.36	2.1e-01	ARFRP1 C5orf56 CUL2 LACC1 NDFIP1 P4HA2 PDLIM4 PNMT RAD50 SLC22A5 SMAD3
Respiratory disease	9.17	10	8	17.8	-0.37	2.1e-01	ARFRP1 C5orf56 LACC1 NDFIP1 P4HA2 PDLIM4 PNMT RAD50 SLC22A5 SMAD3
Ulcerative Colitis	8.49	13	7	15.6	0.96	1.8e-07	AMT ARFRP1 CARD9 CUL2 ICOSLG IGHEP2 IL12B IL23R LRRK2 PEX13 PNMT PTRF TNFSF15
Allergy	7.49	14	9	20.0	0.16	5.3e-01	ARFRP1 C5orf56 CCDC116 IGHEP2 NDFIP1 P4HA2 PDLIM4 PEX13 PNMT PTGER4 RAD50 RP11-373D23.3 SLC22A5 SMAD3
Blood White Count	6.64	18	15	33.3	-0.58	6.2e-03	ADCY7 ADO ARFRP1 C5orf56 CARD9 CCDC116 EIF3C LNPEP NDFIP1 P4HA2 PDE4A PDLIM4 PEX13 PNMT RAD50 RP11-373D23.3 S1PR5 SLC22A5
Hayfever, allergic rhinitis or eczema	5.71	15	9	20.0	0.04	8.9e-01	ARFRP1 C5orf56 CCDC116 IGHEP2 MSTO2P NDFIP1 P4HA2 PDLIM4 PEX13 PNMT PTGER4 RAD50 RP11-373D23.3 SLC22A5 SMAD3
Allergy or Eczema	5.02	15	8	17.8	0.40	1.3e-01	ADAM15 ARFRP1 C5orf56 CCDC116 IGHEP2 IL1RL1 MSTO2P NDFIP1 PDLIM4 PEX13 PNMT PTGER4 RP11-373D23.3 SLC22A5 SMAD3
Medication: Seretide 50 evohaler	4.15	5	0	0.0	-0.76	4.6e-02	C5orf56 P4HA2 PDLIM4 SLC22A5 SMAD3
Blood Platelet Count	3.77	16	14	31.1	-0.38	1.1e-01	ADAM15 ADO ARFRP1 ATG16L1 C5orf56 EIF3C FUT2 IGHEP2 NDFIP1 P4HA2 PDLIM4 PNMT PTGER4 RAD50 RP11-373D23.3 SLC22A5
Medication: Ventolin 100micrograms inhaler	3.75	3	2	4.4	0.00	1.0e+00	NDFIP1 PNMT SMAD3
Standing height	3.22	13	6	13.3	0.73	1.2e-03	ADO C5orf56 CARD9 CCDC116 FUT2 MIER1 P4HA2 PDE4A PDLIM4 PTRF RAD50 RP11-373D23.3 SLC22A5
Height	3.12	17	15	33.3	0.57	9.4e-03	ADO ARFRP1 ATG16L1 C5orf56 CARD9 CCDC116 FUT2 IL1RL1 MIER1 NDFIP1 P4HA2 PDE4A PDLIM4 PTRF RAD50 RP11-373D23.3 SLC22A5
Comparative height size at age 10	3.12	8	7	15.6	0.77	5.3e-03	C5orf56 CARD9 CCDC116 EIF3C FUT2 P4HA2 PDLIM4 SLC22A5
Hand grip strength (right)	3.07	5	4	8.9	0.80	1.8e-02	C5orf56 EIF3C P4HA2 PDLIM4 SLC22A5
Hypothyroidism (self reported)	3.03	4	2	4.4	0.31	6.9e-01	AL133458.1 FUT2 PTPN2 PTRF
Lung FEV1/FVC ratio	2.95	8	6	13.3	0.69	1.9e-02	ADO C5orf56 FUT2 P4HA2 PDLIM4 PNMT SLC22A5 SMAD3
Medication: Levothyroxine sodium	2.93	3	1	2.2	0.00	1.0e+00	AL133458.1 PTPN2 PTRF
Wheeze or whistling in the chest in last year	2.90	4	3	6.7	0.36	6.4e-01	ARFRP1 PNMT SLC22A5 SMAD3
Number of self-reported non-cancer illnesses	2.84	4	0	0.0	0.19	8.1e-01	ARFRP1 FUT2 PDLIM4 SLC22A5
Hand grip strength (left)	2.83	4	4	8.9	0.98	6.4e-05	C5orf56 P4HA2 PDLIM4 SLC22A5
Hypothyroidism/myxoedema (self-reported)	2.74	2	1	2.2	0.00	1.0e+00	AL133458.1 PTRF
Leg fat-free mass (left)	2.70	8	6	13.3	0.89	2.0e-04	ADO C5orf56 EIF3C MSTO2P P4HA2 PDE4A PDLIM4 SLC22A5
Leg predicted mass (left)	2.69	8	6	13.3	0.89	2.1e-04	ADO C5orf56 EIF3C MSTO2P P4HA2 PDE4A PDLIM4 SLC22A5
Lung FVC	2.68	9	6	13.3	-0.88	1.3e-04	ADCY7 ARFRP1 C5orf56 CARD9 EIF3C P4HA2 PDLIM4 PNMT SLC22A5
Hayfever/allergic rhinitis (self-reported)	2.67	2	1	2.2	0.00	1.0e+00	PNMT SMAD3
Leg predicted mass (right)	2.61	9	6	13.3	0.81	1.5e-03	ADO C5orf56 EIF3C MSTO2P P4HA2 PDE4A PDLIM4 RP11-373D23.3 SLC22A5
Leg fat-free mass (right)	2.60	8	6	13.3	0.89	2.3e-04	ADO C5orf56 EIF3C MSTO2P P4HA2 PDE4A PDLIM4 SLC22A5
Whole body water mass	2.55	9	7	15.6	0.88	1.3e-04	ADO C5orf56 CARD9 EIF3C P4HA2 PDE4A PDLIM4 RP11-373D23.3 SLC22A5
Whole body fat-free mass	2.53	9	7	15.6	0.88	1.3e-04	ADO C5orf56 CARD9 EIF3C P4HA2 PDE4A PDLIM4 RP11-373D23.3 SLC22A5
Medication: Bendroflumethiazide	2.50	4	0	0.0	-0.67	2.2e-01	FUT2 P4HA2 PDLIM4 SLC22A5
Basal metabolic rate	2.47	9	6	13.3	0.89	1.3e-04	ADO C5orf56 CARD9 EIF3C P4HA2 PDE4A PDLIM4 RP11-373D23.3 SLC22A5
Trunk fat-free mass	2.43	9	7	15.6	0.88	1.8e-04	ADO C5orf56 CARD9 EIF3C P4HA2 PDE4A PDLIM4 RP11-373D23.3 SLC22A5
Trunk predicted mass	2.42	9	7	15.6	0.88	1.9e-04	ADO C5orf56 CARD9 EIF3C P4HA2 PDE4A PDLIM4 RP11-373D23.3 SLC22A5
Lupus	2.40	1	1	2.2	0.00	1.0e+00	CCDC116
Triglycerides	2.38	1	1	2.2	0.00	1.0e+00	RP11-373D23.3
Father's age at death	2.36	1	0	0.0	0.00	1.0e+00	SLC22A5
Arm predicted mass (left)	2.36	8	7	15.6	0.86	6.1e-04	C5orf56 CARD9 EIF3C P4HA2 PDE4A PDLIM4 RP11-373D23.3 SLC22A5
Taking other prescription medications	2.35	1	1	2.2	0.00	1.0e+00	AL133458.1
Vascular/heart problems diagnosed by doctor	2.32	5	4	8.9	0.34	4.2e-01	ADO C5orf56 FUT2 PDLIM4 SLC22A5
Arm fat-free mass (left)	2.31	8	7	15.6	0.86	6.4e-04	C5orf56 CARD9 EIF3C P4HA2 PDE4A PDLIM4 RP11-373D23.3 SLC22A5
Arm fat-free mass (right)	2.26	8	6	13.3	0.85	8.8e-04	C5orf56 CARD9 EIF3C P4HA2 PDE4A PDLIM4 RP11-373D23.3 SLC22A5
Arm predicted mass (right)	2.24	8	6	13.3	0.85	1.0e-03	C5orf56 CARD9 EIF3C P4HA2 PDE4A PDLIM4 RP11-373D23.3 SLC22A5
Long-standing illness, disability or infirmity	2.24	1	0	0.0	0.00	1.0e+00	AL133458.1
Cardiovascular Disease	2.23	7	4	8.9	0.11	8.2e-01	ADO ATG16L1 C5orf56 FUT2 PDLIM4 RAD50 SLC22A5
Mouth/teeth dental problems: Mouth ulcers	2.21	3	1	2.2	0.00	1.0e+00	IL12B PNMT TNFSF15
Medication for cholesterol, blood pressure or diabetes	2.19	1	0	0.0	0.00	1.0e+00	FUT2
High blood pressure	2.18	6	2	4.4	-0.46	2.2e-01	ADO C5orf56 FUT2 P4HA2 PDLIM4 SLC22A5
Sitting height	2.13	10	6	13.3	0.62	2.3e-02	ADO C5orf56 CARD9 CCDC116 DCTN4 FUT2 MIER1 P4HA2 PDLIM4 SLC22A5
Medication: Blood pressure	2.10	3	1	2.2	-0.99	1.1e-02	P4HA2 PDLIM4 SLC22A5
Hypertension (Self-reported)	2.06	5	3	6.7	-0.29	4.8e-01	ADO C5orf56 FUT2 PDLIM4 SLC22A5
Weight	2.04	8	7	15.6	0.76	6.7e-03	AMT ARFRP1 C5orf56 EIF3C P4HA2 PDE4A PDLIM4 SLC22A5
Forced expiratory volume in 1-second (FEV1), predicted	2.04	4	1	2.2	0.98	6.8e-05	P4HA2 PDE4A PDLIM4 SLC22A5
Rheumatoid Arthritis	2.03	2	1	2.2	0.00	1.0e+00	PNMT PTPN2
Primary Biliary Cirrhosis	2.01	1	1	2.2	0.00	1.0e+00	PNMT
Diastolic blood pressure, automated reading	1.98	7	2	4.4	-0.32	4.8e-01	ADAM15 ADO AMT ARFRP1 LNPEP P4HA2 PDLIM4
Breast Cancer	1.90	1	1	2.2	-0.52	4.8e-01	SLC22A5
Intelligence (Savage-Jansen 2018)	1.86	3	2	4.4	0.00	1.0e+00	AMT EIF3C LNPEP
Birth weight	1.84	1	0	0.0	0.00	1.0e+00	FUT2
Peak expiratory flow (PEF)	1.80	1	0	0.0	0.00	1.0e+00	FUT2
Mouth/teeth dental problems: Dentures	1.79	3	1	2.2	0.00	1.0e+00	FUT2 PNMT RAD50
Fasting Glucose	1.78	1	0	0.0	0.00	1.0e+00	RP11-373D23.3
Trunk fat mass	1.74	3	3	6.7	0.00	1.0e+00	AMT ARFRP1 EIF3C
Qualifications: College or University degree	1.73	3	2	4.4	0.00	1.0e+00	AMT ARFRP1 EIF3C
HDL Cholesterol	1.71	2	2	4.4	0.00	1.0e+00	CCDC116 PNMT
Forced expiratory volume in 1-second (FEV1), Best measure	1.71	5	2	4.4	0.26	6.2e-01	ADO ARFRP1 ICOSLG S1PR5 SLC22A5
Whole body fat mass	1.67	3	3	6.7	0.00	1.0e+00	AMT ARFRP1 EIF3C
Leg fat percentage (left)	1.66	3	3	6.7	0.00	1.0e+00	AMT ARFRP1 EIF3C
Fed-up feelings	1.63	2	0	0.0	0.00	1.0e+00	AMT EIF3C
Trunk fat percentage	1.62	3	3	6.7	0.00	1.0e+00	AMT ARFRP1 EIF3C
Medication: Cholesterol lowering	1.62	1	1	2.2	0.00	1.0e+00	FUT2
Ever smoked	1.60	1	0	0.0	0.00	1.0e+00	ADAM15
Forced expiratory volume in 1-second (FEV1)	1.59	2	1	2.2	0.00	1.0e+00	ARFRP1 SLC22A5
High cholesterol (Self-reported)	1.59	1	1	2.2	0.00	1.0e+00	FUT2
Arm fat mass (right)	1.56	4	2	4.4	-0.11	8.9e-01	AMT ARFRP1 EIF3C MSTO2P
Body fat percentage	1.56	3	3	6.7	0.00	1.0e+00	AMT ARFRP1 EIF3C
Medication: Paracetamol	1.55	1	0	0.0	0.00	1.0e+00	CYLD
Arm fat percentage (right)	1.54	4	2	4.4	-0.12	8.8e-01	AMT ARFRP1 EIF3C MSTO2P
Arm fat percentage (left)	1.54	4	2	4.4	-0.12	8.8e-01	AMT ARFRP1 EIF3C MSTO2P
Verbal and Numeric Reasoning (VNR)	1.51	2	2	4.4	0.00	1.0e+00	AMT EIF3C
Mouth/teeth dental problems	1.51	1	0	0.0	0.00	1.0e+00	FUT2
Leg fat percentage (right)	1.51	4	3	6.7	-0.88	1.2e-01	AMT ARFRP1 EIF3C LNPEP
Arm fat mass (left)	1.51	4	2	4.4	-0.51	4.9e-01	AMT ARFRP1 EIF3C PDE4A
Alcohol intake frequency.	1.49	2	2	4.4	0.00	1.0e+00	EIF3C FUT2
Hip circumference	1.48	4	2	4.4	-0.45	5.5e-01	AMT ARFRP1 EIF3C PDE4A
Fluid intelligence score	1.46	2	2	4.4	0.00	1.0e+00	AMT EIF3C
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.46	3	1	2.2	0.00	1.0e+00	ARFRP1 EIF3C PNMT
Worry (Nagel 2018)	1.45	1	0	0.0	0.00	1.0e+00	MIER1
Body Mass Index (BMI) (2010)	1.43	1	1	2.2	0.00	1.0e+00	EIF3C
Current tobacco smoking	1.42	1	0	0.0	0.00	1.0e+00	ARFRP1
Average weekly spirits intake	1.40	2	0	0.0	0.00	1.0e+00	AMT FUT2
Waist circumference	1.40	3	1	2.2	0.00	1.0e+00	AMT ARFRP1 EIF3C
Past tobacco smoking	1.40	1	0	0.0	0.00	1.0e+00	ADAM15
Suffer from 'nerves'	1.40	1	1	2.2	0.00	1.0e+00	EIF3C
Leg fat mass (left)	1.40	3	3	6.7	0.00	1.0e+00	AMT ARFRP1 EIF3C
LDL Cholesterol	1.38	1	1	2.2	0.00	1.0e+00	FUT2
Age when periods started (menarche)	1.37	1	0	0.0	0.00	1.0e+00	FUT2
Leg fat mass (right)	1.37	3	3	6.7	0.00	1.0e+00	AMT ARFRP1 EIF3C
Smoking Status	1.35	1	0	0.0	0.00	1.0e+00	ARFRP1
Comparative body size at age 10	1.34	2	1	2.2	0.00	1.0e+00	EIF3C FUT2
Smoking status: Current	1.33	1	0	0.0	0.00	1.0e+00	ARFRP1
Medication for cholesterol	1.32	1	0	0.0	0.00	1.0e+00	FUT2
Medication: Simvastatin	1.31	1	1	2.2	0.00	1.0e+00	FUT2
Prostate Cancer	1.30	1	1	2.2	0.00	1.0e+00	ARFRP1
Alcohol intake versus 10 years previously	1.30	2	0	0.0	0.00	1.0e+00	AMT FUT2
Schizophrenia (2014)	1.29	1	0	0.0	0.00	1.0e+00	LACC1
Pack years adult smoking proportion	1.29	1	0	0.0	0.00	1.0e+00	EIF3C
Neuroticism (Nagel 2018)	1.28	1	0	0.0	0.00	1.0e+00	AL133458.1
BMI	1.28	4	3	6.7	-0.20	8.0e-01	AMT ARFRP1 EIF3C MSTO2P
Qualifications: A levels/AS levels or equivalent	1.28	1	1	2.2	0.00	1.0e+00	AMT
Seen doctor (GP) for nerves, anxiety, tension or depression	1.27	1	0	0.0	0.00	1.0e+00	MIER1
Cholesterol lowering medication	1.26	1	0	0.0	0.00	1.0e+00	FUT2
Bipolar Disorder or Schizophrenia	1.22	2	0	0.0	0.00	1.0e+00	FUT2 LACC1
Pulse rate, automated reading	1.18	1	1	2.2	0.00	1.0e+00	AMT
Overall health rating	1.16	1	0	0.0	0.00	1.0e+00	AMT
Body mass index (BMI)	1.15	3	2	4.4	0.00	1.0e+00	AMT EIF3C MSTO2P
Relative age of first facial hair	1.12	1	0	0.0	0.00	1.0e+00	CUL2
Systolic Blood Pressure	1.11	6	2	4.4	0.18	7.3e-01	ADO C5orf56 CCDC116 CISD1 CUL2 FUT2
Systolic blood pressure, automated reading	1.10	1	1	2.2	0.00	1.0e+00	ADO
Forced vital capacity (FVC), Best measure	1.04	1	1	2.2	0.00	1.0e+00	ARFRP1
Impedance of leg (left)	1.03	4	1	2.2	-0.57	4.3e-01	CCDC116 EIF3C MSTO2P PDLIM4
Forced vital capacity (FVC)	1.03	1	1	2.2	0.00	1.0e+00	ARFRP1
Chronotype (morning person)	0.99	1	0	0.0	0.00	1.0e+00	CARD9
Gout (self-reported)	0.96	1	0	0.0	0.00	1.0e+00	RP11-373D23.3
Qualifications: None of the above	0.94	2	1	2.2	0.00	1.0e+00	AMT EIF3C
Blood Red Count	0.92	9	6	13.3	-0.02	9.6e-01	AMT ARFRP1 EIF3C IGHEP2 NDFIP1 PNMT PTGER4 PTPN2 RP11-373D23.3
Qualifications: nursing, teaching	0.91	1	0	0.0	0.00	1.0e+00	AMT
Impedance of leg (right)	0.90	3	1	2.2	0.00	1.0e+00	CCDC116 EIF3C MSTO2P
Medication: Allopurinol	0.85	1	0	0.0	0.00	1.0e+00	RP11-373D23.3
Irritability	0.84	1	0	0.0	0.00	1.0e+00	LNPEP
Heel bone mineral density (BMD) T-score, automated (left)	0.73	1	0	0.0	0.00	1.0e+00	AMT
Heel bone mineral density (BMD) T-score, automated (right)	0.68	1	0	0.0	0.00	1.0e+00	AMT
Impedance of arm (right)	0.67	2	1	2.2	0.00	1.0e+00	NDFIP1 RP11-373D23.3
Waist Hip Ratio (WHR)	0.61	1	0	0.0	0.00	1.0e+00	FUT2
Impedance of arm (left)	0.61	2	1	2.2	0.00	1.0e+00	ADCY7 RP11-373D23.3
Heel T-Score	0.57	2	2	4.4	0.00	1.0e+00	AMT CCDC116
Impedance of whole body	0.54	1	0	0.0	0.00	1.0e+00	RP11-373D23.3
Tanning	0.29	3	2	4.4	0.00	1.0e+00	ADO IL1RL1 MSTO2P
Hair Pigment	0.20	2	1	2.2	0.00	1.0e+00	ADAM15 CUL2

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Putamen basal ganglia	5	0.83	2.0
GTEx	Brain Cortex	8	0.80	1.9
GTEx	Brain Hypothalamus	4	0.71	1.9
GTEx	Brain Nucleus accumbens basal ganglia	7	0.84	1.9
GTEx	Esophagus Gastroesophageal Junction	12	0.87	1.9
GTEx	Esophagus Mucosa	24	0.75	1.9
GTEx	Ovary	7	0.80	1.9
GTEx	Stomach	10	0.72	1.9
GTEx	Vagina	6	0.99	1.9
GTEx	Whole Blood	16	0.84	1.9
NTR	Blood	18	0.76	1.9
The Cancer Genome Atlas	Rectum Adenocarcinoma	6	0.91	1.9
GTEx	Artery Coronary	8	0.71	1.8
GTEx	Brain Caudate basal ganglia	7	0.79	1.8
GTEx	Brain Cerebellar Hemisphere	8	0.56	1.8
GTEx	Brain Cerebellum	8	0.42	1.8
GTEx	Brain Frontal Cortex BA9	4	0.45	1.8
GTEx	Brain Hippocampus	3	0.59	1.8
GTEx	Colon Transverse	9	0.46	1.8
GTEx	Heart Atrial Appendage	11	0.73	1.8
GTEx	Heart Left Ventricle	6	0.41	1.8
GTEx	Lung	20	0.73	1.8
GTEx	Pituitary	6	0.56	1.8
GTEx	Prostate	6	0.75	1.8
GTEx	Skin Not Sun Exposed Suprapubic	16	0.67	1.8
GTEx	Spleen	8	0.59	1.8
The Cancer Genome Atlas	Colon Adenocarcinoma	12	0.63	1.8
The Cancer Genome Atlas	Lung Adenocarcinoma	13	0.48	1.8
The Cancer Genome Atlas	Skin Cutaneous Melanoma	4	0.82	1.8
GTEx	Adipose Visceral Omentum	9	0.46	1.7
GTEx	Adrenal Gland	7	0.50	1.7
GTEx	Artery Aorta	11	0.39	1.7
GTEx	Artery Tibial	22	0.61	1.7
GTEx	Breast Mammary Tissue	8	0.42	1.7
GTEx	Breast Mammary Tissue (Male)	6	0.53	1.7
GTEx	Breast Mammary Tissue (Female)	7	0.46	1.7
GTEx	Cells Transformed fibroblasts	19	0.47	1.7
GTEx	Colon Sigmoid	6	0.43	1.7
GTEx	Esophagus Muscularis	17	0.55	1.7
GTEx	Liver	2	0.29	1.7
GTEx	Nerve Tibial	22	0.53	1.7
GTEx	Pancreas	4	0.25	1.7
GTEx	Skin Sun Exposed Lower leg	19	0.55	1.7
GTEx	Small Intestine Terminal Ileum	2	0.45	1.7
GTEx	Testis	16	0.53	1.7
GTEx	Thyroid	23	0.60	1.7
GTEx	Uterus	2	0.37	1.7
YFS	Blood	21	0.47	1.7
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	6	0.59	1.7
The Cancer Genome Atlas	Glioblastoma Multiforme	3	0.32	1.7
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	13	0.51	1.7
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	9	0.47	1.7
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	4	0.39	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	11	0.47	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	8	0.54	1.7
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	10	0.65	1.7
The Cancer Genome Atlas	Stomach Adenocarcinoma	8	0.51	1.7
The Cancer Genome Atlas	Testicular Germ Cell Tumors	4	0.34	1.7
GTEx	Adipose Subcutaneous	14	0.42	1.6
GTEx	Cells EBV-transformed lymphocytes	4	0.29	1.6
GTEx	Muscle Skeletal	12	0.43	1.6
METSIM	Adipose	18	0.40	1.6
ROSMAP	Brain Pre-frontal Cortex	13	0.31	1.6
CommonMind	Brain Pre-frontal Cortex	19	0.36	1.6
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	7	0.46	1.6
The Cancer Genome Atlas	Breast Invasive Carcinoma	17	0.41	1.6
The Cancer Genome Atlas	Esophageal Carcinoma	3	0.47	1.6
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	18	0.47	1.6
The Cancer Genome Atlas	Brain Lower Grade Glioma	21	0.52	1.6
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	4	0.33	1.6
The Cancer Genome Atlas	Prostate Adenocarcinoma	21	0.49	1.6
The Cancer Genome Atlas	Soft Tissue Sarcoma	3	0.31	1.6
The Cancer Genome Atlas	Thyroid Carcinoma	19	0.40	1.6
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.43	1.6